- Home
- ECOR vs QNCX Comparison
ECOR vs QNCX Comparison
Compare ECOR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- QNCX
- Stock Information
- Founded
- ECOR 2005
- QNCX 2012
- Country
- ECOR United States
- QNCX United States
- Employees
- ECOR N/A
- QNCX N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECOR Health Care
- QNCX Health Care
- Exchange
- ECOR Nasdaq
- QNCX Nasdaq
- Market Cap
- ECOR 111.3M
- QNCX 92.3M
- IPO Year
- ECOR 2018
- QNCX 2019
- Fundamental
- Price
- ECOR $15.90
- QNCX $1.66
- Analyst Decision
- ECOR Strong Buy
- QNCX Strong Buy
- Analyst Count
- ECOR 1
- QNCX 4
- Target Price
- ECOR $25.00
- QNCX $9.50
- AVG Volume (30 Days)
- ECOR 144.8K
- QNCX 147.2K
- Earning Date
- ECOR 03-12-2025
- QNCX 11-13-2024
- Dividend Yield
- ECOR N/A
- QNCX N/A
- EPS Growth
- ECOR N/A
- QNCX N/A
- EPS
- ECOR N/A
- QNCX N/A
- Revenue
- ECOR $23,327,000.00
- QNCX N/A
- Revenue This Year
- ECOR $59.81
- QNCX N/A
- Revenue Next Year
- ECOR $38.49
- QNCX N/A
- P/E Ratio
- ECOR N/A
- QNCX N/A
- Revenue Growth
- ECOR 74.10
- QNCX N/A
- 52 Week Low
- ECOR $5.32
- QNCX $0.51
- 52 Week High
- ECOR $18.67
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ECOR 53.73
- QNCX 40.36
- Support Level
- ECOR $15.50
- QNCX $1.70
- Resistance Level
- ECOR $16.12
- QNCX $1.78
- Average True Range (ATR)
- ECOR 1.20
- QNCX 0.13
- MACD
- ECOR -0.31
- QNCX -0.03
- Stochastic Oscillator
- ECOR 40.17
- QNCX 2.56
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.